
Please try another search
Cassava Sciences, Inc. is a clinical-stage biotechnology company. The Company is focused on developing the drug for the treatment of neurodegenerative diseases, such as Alzheimer's disease. The Company’s products include Simufilam and SavaDx. Its lead therapeutic product candidate, Simufilam, is a proprietary small molecule (oral) drug. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer's brain. The SavaDx, is an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is also developing SavaDx is a quantitative blood-based investigational biomarker/diagnostic to detect and monitor Alzheimer's disease. The Company’s scientific approach for the treatment of Alzheimer's disease seeks to simultaneously progress both neurodegeneration and neuroinflammation.
Name | Age | Since | Title |
---|---|---|---|
Richard Jon Barry | 63 | 2021 | Independent Director |
Grant L. Schoenhard | 77 | 2001 | Member of Scientific Advisory Board |
Patrick J. Scannon | 74 | 2007 | Independent Director |
Robert Z. Gussin | 84 | 2003 | Independent Director |
Nadav Friedmann | 79 | 1998 | Chief Medical Officer & Director |
Remi Barbier | 62 | 1998 | Founder, Chairman, President & CEO |
Sanford R. Robertson | 90 | 1998 | Lead Independent Director |
Michael J. O'Donnell | 64 | 1998 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review